222 related articles for article (PubMed ID: 20668437)
21. NGF serum levels variations in major depressed patients receiving duloxetine.
Martino M; Rocchi G; Escelsior A; Contini P; Colicchio S; de Berardis D; Amore M; Fornaro P; Fornaro M
Psychoneuroendocrinology; 2013 Sep; 38(9):1824-8. PubMed ID: 23507186
[TBL] [Abstract][Full Text] [Related]
22. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
23. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
24. VEGF plasma level variations in duloxetine-treated patients with major depression.
Fornaro M; Rocchi G; Escelsior A; Contini P; Ghio M; Colicchio S; De Berardis D; Amore M; Fornaro P; Martino M
J Affect Disord; 2013 Nov; 151(2):590-595. PubMed ID: 23871390
[TBL] [Abstract][Full Text] [Related]
25. Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study.
Robertson B; Wang L; Diaz MT; Aiello M; Gersing K; Beyer J; Mukundan S; McCarthy G; Doraiswamy PM
J Clin Psychiatry; 2007 Feb; 68(2):261-7. PubMed ID: 17335325
[TBL] [Abstract][Full Text] [Related]
26. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
Montejo AL; Perahia DG; Spann ME; Wang F; Walker DJ; Yang CR; Detke MJ
J Sex Med; 2011 Mar; 8(3):773-82. PubMed ID: 21091877
[TBL] [Abstract][Full Text] [Related]
27. Duloxetine: a review of its use in the treatment of major depressive disorder.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
[TBL] [Abstract][Full Text] [Related]
28. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
29. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
30. Duloxetine effects on striatal resting-state functional connectivity in patients with major depressive disorder.
Wang L; An J; Gao HM; Zhang P; Chen C; Li K; Mitchell PB; Si TM
Hum Brain Mapp; 2019 Aug; 40(11):3338-3346. PubMed ID: 31066977
[TBL] [Abstract][Full Text] [Related]
31. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder.
Meighen KG
J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):121-7. PubMed ID: 17343560
[TBL] [Abstract][Full Text] [Related]
32. Time course of depression-symptom improvement during treatment with duloxetine.
Hirschfeld RM; Mallinckrodt C; Lee TC; Detke MJ
Depress Anxiety; 2005; 21(4):170-7. PubMed ID: 16035056
[TBL] [Abstract][Full Text] [Related]
33. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine.
Marangell LB; Clauw DJ; Choy E; Wang F; Shoemaker S; Bradley L; Mease P; Wohlreich MM
Pain; 2011 Jan; 152(1):31-37. PubMed ID: 20598442
[TBL] [Abstract][Full Text] [Related]
34. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis.
Spielmans GI
Psychother Psychosom; 2008; 77(1):12-6. PubMed ID: 18087203
[TBL] [Abstract][Full Text] [Related]
35. Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background?
Fornaro M; Bandini F; Ogliastro C; Cordano C; Martino M; Cestari L; Escelsior A; Rocchi G; Colicchio S; Perugi G
J Affect Disord; 2011 Dec; 135(1-3):154-9. PubMed ID: 21820182
[TBL] [Abstract][Full Text] [Related]
36. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data.
Mancini M; Gianni W; Rossi A; Amore M
Expert Opin Pharmacother; 2009 Apr; 10(5):847-60. PubMed ID: 19351233
[TBL] [Abstract][Full Text] [Related]
37. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics.
Perahia DG; Kajdasz DK; Royer MG; Walker DJ; Raskin J
Int Clin Psychopharmacol; 2006 Sep; 21(5):285-95. PubMed ID: 16877900
[TBL] [Abstract][Full Text] [Related]
39. A word of caution about the implied role for duloxetine in pain management.
Leo RJ
J Clin Psychiatry; 2003 Oct; 64(10):1270. PubMed ID: 14658982
[No Abstract] [Full Text] [Related]
40. Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine.
Schneider E; Linden M; Weigmann H; Wagner T; Quail D; Hundemer HP; Hegerl U
BMC Psychiatry; 2011 Sep; 11():150. PubMed ID: 21933428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
